Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

In times of market uncertainties, high-dividend yield stocks are ideal investment choices for their qualities like stable passive income, protection against inflation, and price appreciation. Thus, ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Essentia Health is offering immunization options for kids and adults to protect against respiratory syncytial virus, or RSV.

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.